| 1 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
FOXA2 and OTX2 double-positivity was the specific release specification used to confirm correct ventral midbrain dopamine progenitor identity, whereas SOX1/PAX6 were used to detect unwanted off-target neural cells and GIRK2/ALDH1A1/LMX1A/EN1 were markers used later to confirm mature dopaminergic neuron identity after transplantation, not batch purity at release. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", Manufacturing and quality control of STEM-PD, page 1301 of the pdf file, and Table 1,release specifications, state that purity/identity was assessed by flow cytometry for FOXA2 and OTX2, with result batch #3 showing 98.7% double-positive purity, meeting the greater than or equal to 70% release criterion. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI in medical imaging is framed as supporting clinical decision-making, interpreting scans, and improving productivity and patient outcomes, not reducing equipment costs, automating general admin work, marketing products, or conducting research, none of which capture the article's stated purpose for medical AI. |
Found in the article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Section 1 "Introduction and motivation", states that AI is anticipated to radically increase the speed, quality, and value of work by healthcare professionals, addressing rising diagnostic workloads and human error to improve productivity and clinical outcomes. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI-generated diagnostic recommendations are described as forming the basis of a second medical opinion supporting clinicians, not increasing radiologist workload, slowing diagnosis, replacing scheduling systems, or raising costs, none of which match the article's framing of AI's benefits. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Section 1 "Introduction and motivation", describes AI use cases including interpreting medical images to generate diagnostic recommendations and personalized treatment plans that act as a second medical opinion, forming the basis of pre-populated preliminary reports. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy is defined as a healthcare professional's general level of understanding and knowledge of AI, shaped by their education, training, and experience with it, not machine repair skills, historical knowledge, legal expertise, or financial management, none of which the article associates with this factor. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Table 3 "Key factors underpinning healthcare professional acceptability of AI", defines AI literacy as the level of understanding and knowledge healthcare professionals have concerning AI in general, as reflected by their education, training, and experience with it. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The article identifies trust, workflow integration, system understanding, and technology receptiveness as four of the twelve established factors shaping AI acceptability, but machine appearance or color is never discussed anywhere in the review, making it a fabricated, irrelevant distractor. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Table 3 "Key factors underpinning healthcare professional acceptability of AI", lists trust, workflow integration, system understanding, and technology receptiveness among the twelve inductively extracted factors, with no factor related to physical appearance or color. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence describes how expectations from colleagues, department heads, and management shape a professional's willingness to use AI, not budgeting decisions, marketing strategy, or the AI's actual diagnostic performance, none of which this factor addresses. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Table 3 "Key factors underpinning healthcare professional acceptability of AI", defines social influence as the extent to which healthcare professionals perceive their use of AI as expected and encouraged by influencing agents important to them, such as colleagues, department heads, or management. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
Perceived threat specifically refers to fears that AI will replace or devalue a professional's role rather than empower them, not IT workload increases, reduced patient interaction, or physical space requirements, none of which the article defines this factor around. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Table 3 "Key factors underpinning healthcare professional acceptability of AI", defines perceived threat as the extent to which healthcare professionals perceive AI as threatening their professional role at an individual and industry level, compared to being an empowering tool. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
The article stresses that high technical performance alone isn't enough, AI also needs to be designed around clinical workflows, varying levels of AI literacy, and healthcare professions' cultural, ethical, and safety norms, not simply cost reduction or aggressive marketing, neither of which the article recommends. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Abstract's Conclusion and Section 5 "Conclusion", state that increasing AI acceptability will critically require designing human-centred AI systems that go beyond high algorithmic performance to consider accessibility, workflow practices, and the ethical/safety norms of healthcare professions. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The "system usage" category groups factors related to human-computer interaction and user experience, value proposition, burden, self-efficacy, and workflow integration, not personal preferences alone, facility location, age/experience, or insurance type, none of which belong to this category. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Section 3.8 "Factors influencing healthcare professional acceptability of AI", groups system usage factors as entailing value proposition, self-efficacy, burden, and workflow integration. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality reflects whether AI fits with healthcare professionals' value systems and their profession's norms, such as safe patient-data handling, not pricing decisions, purely legal matters, irrelevance in medicine, or manufacturing concerns, none of which the article associates with this factor. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Table 3 "Key factors underpinning healthcare professional acceptability of AI", defines ethicality as the extent to which healthcare professionals perceive AI as fitting with their value system and that of the medical profession, such as safe management of patient data privacy. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article calls for future studies to use mixed-methods approaches that combine self-reported data with observational and technical usage data, better grounding research in real clinical workflow context, not focusing solely on economics, prioritizing speed over accuracy, or restricting research to large hospitals, none of which the article recommends. |
The article "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals: A scoping review", Section 4.8 "Future work and direction", recommends a more robust, mixed-methods study design that triangulates survey/interview data with observational and technical system data, and stresses establishing user context and understanding the concrete AI-assisted workflow to better inform future acceptability research. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson's disease is caused by progressive loss of midbrain dopamine neurons, so the therapy's whole rationale is transplanting stem-cell-derived dopamine progenitors to physiologically restore dopamine release, not to increase general brain plasticity, boost cognition broadly, promote neurogenesis elsewhere in the brain, or increase brain size, none of which describe the treatment's targeted mechanism. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", Introduction, explains that PD is characterized by loss of midbrain dopamine neurons, and that cell replacement therapies aim to provide physiological, targeted release of dopamine to restore motor function, directly replacing the neurons lost to the disease. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
Rats were used for both the main GLP safety study such as toxicity, tumorigenicity, biodistribution and the efficacy studies, motor recovery testing, that formed the core preclinical data package, a minipig was used separately only to test the surgical delivery device's feasibility in a larger brain, not for the primary safety/efficacy evaluation, and monkeys, mice, and rabbits were not used at all. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", "GLP safety testing in nude rats" and "STEM-PD grafts are rich in DA neurons... reverse amphetamine-induced rotations in rats" describe the core 39-week safety study and the long-term efficacy study, both conducted in immunodeficient nude rats. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The formal GLP safety study tracking toxicity, tumorigenicity, and biodistribution ran across this timeframe, with animals assessed at multiple points such as 4, 26, and 39 weeks, roughly 9 months total, not the shorter or longer durations listed. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", "Summary" and "GLP safety testing in nude rats," state STEM-PD showed no adverse effects or tumor formation in rats up to 9 months, with the study spanning 39 weeks. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The approved human trial is specifically designed as a combined early-safety and preliminary-efficacy study in 8 patients, not a standalone Phase I, later-stage Phase II, or Phase III/IV trial involving larger populations. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", "Summary" and "STEM-PD clinical trial design," describe the approved trial as a single-arm, first-in-human, phase I/IIa dose-escalation study assessing safety, tolerability, and secondary efficacy endpoints. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The manufacturing protocol follows Good Manufacturing Practice (GMP) standards required for regulatory approval, using controlled, directed differentiation steps rather than spontaneous or random processes, and undergoes extensive regulatory testing rather than skipping it. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", Manufacturing and quality control of STEM-PD, describes STEM-PD as generated using a GMP-compliant protocol for dopamine progenitor cell differentiation with scalable, reproducible manufacturing. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The GLP study found no treatment-related effects on survival, weight, organs, or behavior, and no tumor formation in STEM-PD-treated animals, unlike the undifferentiated stem cell control group, which did develop tumors, the opposite of the other listed outcomes. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", GLP safety testing in nude rats, states the safety study found no treatment-related adverse effects, and biodistribution testing confirmed no human cells were detected outside the transplanted brain hemisphere. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
STEM-PD grafts matured into functional dopamine neurons that fully reversed amphetamine-induced rotational abnormalities in the rat Parkinson's model, unlike the other options describing failure, non-differentiation, or unwanted effects, none of which matched the actual findings. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", reports that transplantation led to full recovery from motor asymmetry by 24 weeks post-transplantation. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b fine-tunes patterning toward a caudal ventral midbrain identity and SHH drives ventralization, both steps guiding stem cells toward the correct dopamine-progenitor fate, not preventing differentiation, triggering cell death, enhancing pluripotency, or being irrelevant. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD", Manufacturing and quality control of STEM-PD, describes SHH as used for ventralization to obtain ventral midbrain progenitor cells, and FGF8b as added to fine-tune patterning toward a caudal ventral midbrain fate. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The key efficacy measure was amphetamine-induced rotational behavior, used as a proxy for motor function, which showed significant recovery after transplantation, not anxiety, cognition, lifespan, or brain size, none of which were the study's efficacy endpoints. |
The article "Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD",STEM-PD grafts are rich in DA neurons... reverse amphetamine-induced rotations in rats, identifies amphetamine-induced rotational assessment as the primary behavioral efficacy measure, showing significant motor recovery post-transplantation. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|